WALTHAM, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter
Potential first-in-class, oral specific orexin- 2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar to or lower than the rate observed in the placebo group Improves depressive symptoms and sleep
WALTHAM, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2019
WALTHAM, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. Thomas Roth and Dr.
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, showed improvement with a
Management to host conference call WALTHAM, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of roluperidone
WALTHAM, Mass. and SOMERSET , N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, and Catalent , the leading global
WALTHAM, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on October 1, 2019 ,
